Amgen Inc. $AMGN Shares Bought by Patriot Financial Group Insurance Agency LLC

Posted by Stanley Muller on Jun 29th, 2026

Patriot Financial Group Insurance Agency LLC raised its holdings in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 301.9% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,838 shares of the medical research company’s stock after buying an additional 5,888 shares during the quarter. Patriot Financial Group Insurance Agency LLC’s holdings in Amgen were worth $2,758,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of AMGN. Norges Bank acquired a new stake in Amgen in the 4th quarter valued at about $2,164,162,000. Capital World Investors lifted its stake in Amgen by 22.9% in the 4th quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock worth $7,560,249,000 after purchasing an additional 4,302,237 shares in the last quarter. State Street Corp boosted its holdings in shares of Amgen by 4.4% during the 4th quarter. State Street Corp now owns 30,591,403 shares of the medical research company’s stock worth $10,012,872,000 after purchasing an additional 1,287,310 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Amgen by 7.8% during the 4th quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock worth $4,665,822,000 after purchasing an additional 1,035,779 shares during the last quarter. Finally, Amundi boosted its holdings in shares of Amgen by 41.1% during the 4th quarter. Amundi now owns 3,396,945 shares of the medical research company’s stock worth $1,111,854,000 after purchasing an additional 988,856 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Price Performance

AMGN stock opened at $358.61 on Monday. The business’s fifty day moving average price is $340.70 and its 200 day moving average price is $346.38. Amgen Inc. has a 12-month low of $269.77 and a 12-month high of $391.29. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65. The company has a market capitalization of $193.54 billion, a PE ratio of 24.96, a P/E/G ratio of 3.60 and a beta of 0.42.

Amgen (NASDAQ:AMGN – Get Free Report) last announced its earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. The company had revenue of $8.62 billion during the quarter, compared to analysts’ expectations of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.Amgen’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same period last year, the business posted $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, sell-side analysts anticipate that Amgen Inc. will post 22.38 EPS for the current year.

Insider Activity at Amgen

In related news, SVP Nancy A. Grygiel sold 1,237 shares of Amgen stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the transaction, the senior vice president owned 7,009 shares in the company, valued at approximately $2,269,023.57. The trade was a 15.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.85% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on AMGN. Guggenheim cut their price target on Amgen from $351.00 to $340.00 and set a “neutral” rating for the company in a report on Monday, May 4th. Erste Group Bank reissued a “hold” rating on shares of Amgen in a research note on Tuesday, May 5th. Canaccord Genuity Group assumed coverage on Amgen in a report on Monday, April 20th. They issued a “hold” rating and a $366.00 target price for the company. Leerink Partners restated a “market perform” rating and issued a $355.00 target price on shares of Amgen in a report on Thursday, March 5th. Finally, Mizuho raised their target price on Amgen from $295.00 to $303.00 and gave the stock a “neutral” rating in a research note on Tuesday, June 16th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, fifteen have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Amgen has a consensus rating of “Hold” and a consensus price target of $354.42.

View Our Latest Report on AMGN

Amgen Company Profile

(Free Report)

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.